Home » Drug Information

View By: Year Company Therapeutic Areas Drug Names 

FDA-Approved Drugs

The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Drug information typically includes the drug name, approval status, indication of use, and clinical trial results.

Find out more about the types of drugs included in this listing.

Year: 2009 | 2008 | [2007] | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995

Cardiology/Vascular Diseases

Azor (amlodipine besylate; olmesartan medoxomil); Daiichi Sankyo; For the treatment of hypertension, Approved September 2007

Fenofibrate; LifeCycle Pharma; For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia, Approved August 2007

Letairis (ambrisentan); Gilead; For the treatment of pulmonary arterial hypertension, Approved June 2007

Soliris (eculizumab); Alexion Pharm; For the treatment of paroxysmal nocturnal hemoglobinuria, Approved March 2007

Tekturna (aliskiren); Novartis; For the treatment of hypertension, Approved March 2007

Dermatology/Plastic Surgery

Altabax (retapamulin); GlaxoSmithKline; For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007

Extina (ketoconazole); Stiefel; For the treatment of seborrheic dermatitis, Approved June 2007

Xyzal (levocetirizine dihydrochloride); UCB; For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007

Endocrinology

Evamist (estradiol); Vivus; For the treatment of moderate to severe vasomotor symptoms due to menopause, Approved July 2007

Fenofibrate; LifeCycle Pharma; For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia, Approved August 2007

Somatuline Depot (lanreotide acetate); Beaufour Ipsen; For the treatment of acromegaly, Approved August 2007

Supprelin LA (histrelin acetate); Indevus Pharmaceuticals; For the treatment of central precocious puberty, Approved May 2007

Hematology

Kuvan (sapropterin dihydrochloride); BioMarin Pharmaceuticals; For the treatment of hyperphenylalaninemia due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria, Approved December 2007

Mircera (methoxy polyethylene glycol-epoetin beta); Roche; For the treatment of anemia associated with chronic renal failure, Approved November 2007

Soliris (eculizumab); Alexion Pharm; For the treatment of paroxysmal nocturnal hemoglobinuria, Approved March 2007

Immunology/Infectious Diseases

Altabax (retapamulin); GlaxoSmithKline; For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007

AzaSite (azithromycin); InSite Vision; For the treatment of bacterial conjunctivitis, Approved April 2007

Doribax (doripenem); Johnson & Johnson; For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007

Extina (ketoconazole); Stiefel; For the treatment of seborrheic dermatitis, Approved June 2007

Isentress (raltegravir); Merck; For the treatment of HIV-1, Approved October 2007

Selzentry (maraviroc); Pfizer; For the treatment of CCR5-tropic HIV-1, Approved August 2007

Veramyst (fluticasone furoate); GlaxoSmithKline; For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007

Xyzal (levocetirizine dihydrochloride); UCB; For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007

Musculoskeletal

Amrix (cyclobenzaprine hydrochloride extended release); Cephalon; For the treatment of muscle spasm associated with acute, painful musculoskeletal conditions, Approved February 2007

Evista (raloxifene hydrochloride); Eli Lilly; For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007

Reclast (zoledronic acid); Novartis; For the treatment of postmenopausal osteoporosis, Approved August 2007

Reclast (zoledronic acid); Novartis; For the treatment of Paget's disease, Approved April 2007

Somatuline Depot (lanreotide acetate); Beaufour Ipsen; For the treatment of acromegaly, Approved August 2007

Nephrology/Urology

Doribax (doripenem); Johnson & Johnson; For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007

Mircera (methoxy polyethylene glycol-epoetin beta); Roche; For the treatment of anemia associated with chronic renal failure, Approved November 2007

Renvela (sevelamer carbonate); Genzyme; For the control of serum phosphorus in patients with chronic kidney disease on dialysis, Approved October 2007

Torisel (temsirolimus); Wyeth; For the treatment of renal cell carcinoma, Approved May 2007

Neurology

Amrix (cyclobenzaprine hydrochloride extended release); Cephalon; For the treatment of muscle spasm associated with acute, painful musculoskeletal conditions, Approved February 2007

Exelon (rivastigmine tartrate); Novartis; For the treatment of Alzheimer's and Parkinson's disease-related dementia, Approved July 2007

Neupro (rotigotine); Schwarz Pharma; For the treatment of Parkinson's disease, Approved May 2007

Nuvigil (armodafinil); Cephalon; For the treatment of excessive sleepiness, Approved June 2007

Vyvanse (Lisdexamfetamine Dimesylate); New River; For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007

Obstetrics/Gynecology

Evamist (estradiol); Vivus; For the treatment of moderate to severe vasomotor symptoms due to menopause, Approved July 2007

Evista (raloxifene hydrochloride); Eli Lilly; For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007

Reclast (zoledronic acid); Novartis; For the treatment of postmenopausal osteoporosis, Approved August 2007

Oncology

Evista (raloxifene hydrochloride); Eli Lilly; For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women, Approved September 2007

Hycamtin (topotecan hydrochloride); GlaxoSmithKline; For the treatment of small cell lung cancer, Approved October 2007

Ixempra (ixabepilone); Bristol-Myers Squibb; For the treatment of breast cancer, Approved October 2007

Tasigna (nilotinib hydrochloride monohydrate); Novartis; For the treatment of chronic myelogenous leukemia, Approved October 2007

Torisel (temsirolimus); Wyeth; For the treatment of renal cell carcinoma, Approved May 2007

Tykerb (lapatinib); GlaxoSmithKline; For the treatment of breast cancer, Approved March 2007

Ophthalmology

AzaSite (azithromycin); InSite Vision; For the treatment of bacterial conjunctivitis, Approved April 2007

Otolaryngology

Veramyst (fluticasone furoate); GlaxoSmithKline; For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007

Xyzal (levocetirizine dihydrochloride); UCB; For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007

Pediatrics/Neonatology

Altabax (retapamulin); GlaxoSmithKline; For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007

Supprelin LA (histrelin acetate); Indevus Pharmaceuticals; For the treatment of central precocious puberty, Approved May 2007

Veramyst (fluticasone furoate); GlaxoSmithKline; For the treatment of seasonal and perennial allergic rhinitis, Approved April 2007

Vyvanse (Lisdexamfetamine Dimesylate); New River; For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007

Xyzal (levocetirizine dihydrochloride); UCB; For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007

Zingo (lidocaine hydrochloride monohydrate); Anesiva; For local analgesia prior to venipuncture or peripheral intravenous cannulation, in children 3 to 18 years of age, Approved August 2007

Psychiatry/Psychology

Vyvanse (Lisdexamfetamine Dimesylate); New River; For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007

Pulmonary/Respiratory Diseases

Letairis (ambrisentan); Gilead; For the treatment of pulmonary arterial hypertension, Approved June 2007

Xyzal (levocetirizine dihydrochloride); UCB; For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007